Key Highlights
• NBP shares fell approximately 7.58 percent to $1.83 shortly after market open, down from a prior close of $1.98.
• Net loss widened to $37.9 million for the six months ended June 30, 2026, compared to $8.7 million a year earlier.
• The company held $215.9 million in cash and equivalents as of June 30, providing runway through 2028 milestones.
• NovaBridge plans to initiate a registrational Phase 3 study for lead drug givastomig as early as year-end 2026.
Shares Slide as Market Digests H1 Results
NovaBridge Biosciences (NASDAQ:NBP) shares fell approximately 7.58 percent to $1.83 shortly after market open, down from a prior close of $1.98, as the market reacted to first half 2026 financial results released before the opening bell. The decline places the stock among the session's early decliners, with the move reflecting investor focus on the widened net loss reported for the period rather than the pipeline progress the company also detailed.
NovaBridge is a Rockville, Maryland-based clinical-stage biopharmaceutical company that identifies differentiated therapeutic opportunities and advances them through oncology and ophthalmology development programs. The company applies a disciplined development, financing, and partnering strategy to its pipeline, which is currently led by two programs: givastomig in gastric cancer and VIS-101 in retinal vascular disease.
Net Loss Widens on Higher Clinical Spend
Net loss widened to $37.9 million for the six months ended June 30, 2026, compared to $8.7 million in the prior-year period, a roughly fourfold increase that appears to be weighing on sentiment. Net loss per share attributable to ordinary shareholders came in at $0.14, compared to $0.05 a year earlier.
The increase was driven primarily by higher Research and Development spending tied to clinical development activities for givastomig, alongside continued build-out of the company's development capabilities. Research and development expenses rose to $14.3 million from $4.1 million a year earlier. Administrative expenses also increased significantly, to $26.4 million from $8.3 million, reflecting higher share-based compensation tied to 2025 Equity awards, increased personnel costs as the organization expanded, and a one-time write-off of deferred offering costs related to a previously proposed dual listing that was not pursued.
Pipeline Milestones Provide Some Offset
Despite the wider loss, the company pointed to continued progress across its two lead programs as evidence that its Capital is being deployed toward near-term catalysts. Givastomig, a bispecific antibody targeting Claudin 18.2-positive gastric cancer, is on track for a potential registrational Phase 3 study as early as year-end 2026 under a possible Accelerated Approval Pathway. That timeline follows positive Phase 1b dose expansion data showing response rates of 77 percent and 73 percent at two dose levels, along with an FDA Fast Track Designation granted to the program in June.
VIS-101, an ophthalmology candidate for neovascular retinal diseases developed through majority-owned Subsidiary Visara, is progressing toward initiation of a Phase 2b study in the second half of 2026, following positive Phase 2a data reported earlier in the year that showed favorable safety and encouraging durability in patients with wet age-related macular degeneration.
The company also strengthened its Leadership team during the period, appointing a new Chief Executive Officer to oversee strategy, governance, and capital allocation, alongside new commercial leadership and new leadership at the Visara ophthalmology subsidiary.
Cash Position Provides Runway
As of June 30, 2026, the company held $215.9 million in cash, cash equivalents, short-term investments, and equity investments at fair value, down from $260.5 million in total Assets at the end of 2025. Management has said this cash position is sufficient to fund the portfolio through several anticipated clinical and strategic milestones, including a planned Phase 3 interim data readout for givastomig in 2028. Net cash used in Operating Activities was $32.9 million for the six-month period, compared to $7.8 million a year earlier, reflecting the step-up in spending across both research and administrative functions.
What Investors May Watch Next
Market participants are likely to watch for the poster presentation of givastomig's Phase 1b combination data at a major European oncology congress in late October, followed by the planned Phase 3 initiation by year-end. VIS-101's advancement into its Phase 2b program, along with how the company manages its cash runway against the pace of spending increases seen in this reporting period, are additional factors that may shape sentiment in the coming months.
Conclusion
NovaBridge shares fell approximately 7.58 percent to $1.83 shortly after market open, as investors weighed a widened net loss and higher spending against continued clinical progress on the company's lead pipeline programs. Whether the stock stabilizes may depend on execution against the givastomig Phase 3 initiation timeline and how the company manages its cash position through upcoming milestones.






Please wait processing your request...